Incremental cost-effectiveness analysis of tyrosine kinase inhibitors in advanced non-small cell lung cancer with mutations of the epidermal growth factor receptor in Colombia.
Saved in:
| Title: | Incremental cost-effectiveness analysis of tyrosine kinase inhibitors in advanced non-small cell lung cancer with mutations of the epidermal growth factor receptor in Colombia. |
|---|---|
| Authors: | Lasalvia P; Health Economics Department, Neuroeconomix, Bogota, Colombia., Hernández F; Health Economics Department, Neuroeconomix, Bogota, Colombia., Gil-Rojas Y; Health Economics Department, Neuroeconomix, Bogota, Colombia., Rosselli D; Clinical Epidemiology and Biostatistics Department, School of Medicine, Pontificia Universidad Javeriana, Bogotá, Colombia. |
| Source: | Expert review of pharmacoeconomics & outcomes research [Expert Rev Pharmacoecon Outcomes Res] 2021 Aug; Vol. 21 (4), pp. 821-827. Date of Electronic Publication: 2020 Jul 07. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Taylor & Francis Country of Publication: England NLM ID: 101132257 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8379 (Electronic) Linking ISSN: 14737167 NLM ISO Abbreviation: Expert Rev Pharmacoecon Outcomes Res Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1744-8379 |
|---|---|
| DOI: | 10.1080/14737167.2020.1779063 |
